At year-end 2020, according to NHSU (National Health Service of Ukraine https://nszu.gov.ua/e-data/dashboard/reimb-manufacturer-details),* Farmak remains a leader under the Affordable Medicines National Prescription Drugs Cost Reimbursement Program (Affordable Medicines Program) in the categories of the medicinal products where it is represented.
Farmak participates in the reimbursement program in two disease groups: cardiovascular diseases and type II diabetes mellitus. The following medicinal products manufactured by the Company are supplied: Aladin-Farmak and Amlodipine, Bisoprol, Glibenclamide, Diaglizide, Enalozid Mono, Trombonet-Farmak, Metoprolol and Diaformin.
The Company’s total share in the reimbursement program in 2020 is 14.5% in UAH reimbursement or 15.3% in daily doses. In terms of number of prescriptions, this equals to 14.7% or 1.7 million prescriptions.
“We have been actively cooperating with the Affordable Medicines Program since the program launch in 2017. Farmak is largely represented in Diabetes section, as the endocrinology area is one of the Company’s focuses. We manufacture insulin using the technology of the American company Eli Lilly, a world leader in this field. The majority of insulins supplied by Farmak is available under the program at no extra cost to the patient (a separate Insulin Reimbursement Program). This brings us closer to our goal of making treatment with world-class quality medicinal products available to every Ukrainian,” noted Volodymyr Kostiuk, JSC Farmak’s Chief Executive Officer.
The Affordable Medicines Program was launched in Ukraine in 2017. The Program is aimed at reducing the financial burden on patients and increasing the availability of medicinal products.
Since April 1, 2019, the Program has been administered by the NHSU and is an integral part of the Medical Guarantee Program.
Under the reimbursement program, patients with cardiovascular diseases, type II diabetes mellitus or bronchial asthma can be provided with medicinal products for free or with a small additional charge.
Approximately 2.5 million patients in Ukraine benefit from the Affordable Medicines Program.
Farmak took the fourth place in the sustainable development rating published by Korrespondent.net. The rating was developed and compiled by experts of Dengi.ua and Korrespondent.net in partnership with the UN Global Compact Network Ukraine. The evaluation of all rating participants was based on ESG (Environmental, Social and Corporate Governance) criteria. T...
reputation management quality In mid-May 2021, PR-Service agency presented the data on the annual rating Reputational ACTIVists. Farmak took the second place among pharmaceutical manufacturers and importers operating in Ukraine. Corporate reputation management quality rating has been compiled for more than 15 years. As the organizers say, the rating i...
At the beginning of 2021, the representatives of the Republic of Belarus inspected Farmak’s manufacturing, warehouse, laboratory facilities and the functioning of its pharmaceutical quality system. Following the inspection, the Company’s facilities engaged in manufacturing of finished medicinal products have got the EAEU GMP Certificate. The EAEU GMP Certifi...